**SUPPLEMENTARY**

**A. Exclusion Criteria [20]**

|  |
| --- |
| * Current symptoms are fully explained by major depressive disorder or bipolar disorder. * Pre-existing conditions that may cause cognitive impairment, or symptoms similar to those seen in post-COVID-19 condition (e.g., ADHD, major neurocognitive disorder, schizophrenia, chronic fatigue syndrome [CFS]/ encephalitis meningitis [EM]), as assessed by Mini International Neuropsychiatric Interview (MINI) 7.0.2. * Inability to follow study procedures. * Known intolerance to vortioxetine and/or prior trial of vortioxetine with demonstrated inefficacy. * If participants are currently taking other antidepressants, they will be asked to discontinue the antidepressant for 2-4 weeks in order to participate in the study. * Patients on other antidepressants are allowed to participate only if the antidepressant is prescribed at subtherapeutic doses for a primary indication other than mood disorders. Participants will be made aware in the consent form that the combination of the two antidepressants would be considered investigational and that the safety/efficacy profiles are unknown 28–30. * Current alcohol or substance use disorder. * Inability to provide consent. * Current alcohol and/or substance use disorder as confirmed by the M.I.N.I 7.0.2. * Presence of comorbid psychiatric disorder that is a primary focus of clinical concern as confirmed by the M.I.N.I. 7.0.2. * Medications approved and/or employed off-label for cognitive dysfunction (e.g., psychostimulants). * Any medication for a general medical disorder that, in the opinion of the investigator, may affect cognitive function. * Use of benzodiazepines within 12 hours of cognitive assessments. * Consumption of alcohol within 8 hours of cognitive assessments. * Physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments. * Diagnosed reading disability or dyslexia. * Clinically significant learning disorder by history. * Electroconvulsive therapy (ECT) in the last 6 months. * History of moderate or severe head trauma (e.g., loss of consciousness for >1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system. * Pregnant and/or breastfeeding. * Received investigational agents as part of a separate study within 30 days of the screening visit. * Actively suicidal/presence of suicidal ideation or evaluated as being at suicide risk (as per clinical judgment). * Currently receiving treatment with Monoamine Oxidase Inhibitors (MAOIs) antidepressants, antibiotics such as linezolid, or intravenous methylene blue. * Previous hypersensitivity reaction to vortioxetine or any components of the formulation. Angioedema has been reported in patients treated with vortioxetine. * Serotonin syndrome. * Abnormal bleeding. * Previous history of mania/hypomania. * Angle closure glaucoma. * Hyponatremia. * Moderate hepatic impairment. * Active seizure disorder/epilepsy, not controlled by medication (per study physician assessment). * Presence of any unstable medical conditions. |